PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
Programmed Cell Death 1 Receptor
Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT01592370.).